404 related articles for article (PubMed ID: 18035189)
41. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
Whitlock JA; Malvar J; Dalla-Pozza L; Goldberg JM; Silverman LB; Ziegler DS; Attarbaschi A; Brown PA; Gardner RA; Gaynon PS; Hutchinson R; Huynh VT; Jeha S; Marcus L; Messinger Y; Schultz KR; Cassar J; Locatelli F; Zwaan CM; Wood BL; Sposto R; Gore L
Pediatr Blood Cancer; 2022 Nov; 69(11):e29901. PubMed ID: 35989458
[TBL] [Abstract][Full Text] [Related]
42. Older and new purine nucleoside analogs for patients with acute leukemias.
Robak P; Robak T
Cancer Treat Rev; 2013 Dec; 39(8):851-61. PubMed ID: 23566572
[TBL] [Abstract][Full Text] [Related]
43. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
Dyakonova YY; Bydanov OI; Popov AM; Olshanskaya YV; Boichenko EG; Aleynikova OV; Maschan MA; Shelikhova LN; Litvinov DV; Khachatryan LA; Ponomareva NI; Fechina LG; Novichkova GA; Pashanov ED; Karachunskiy AI
Ter Arkh; 2018 Aug; 90(7):38-50. PubMed ID: 30701921
[TBL] [Abstract][Full Text] [Related]
44. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response.
Gandhi V; Plunkett W; Rodriguez CO; Nowak BJ; Du M; Ayres M; Kisor DF; Mitchell BS; Kurtzberg J; Keating MJ
J Clin Oncol; 1998 Nov; 16(11):3607-15. PubMed ID: 9817282
[TBL] [Abstract][Full Text] [Related]
45. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.
Robak T; Lech-Maranda E; Korycka A; Robak E
Curr Med Chem; 2006; 13(26):3165-89. PubMed ID: 17168705
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins.
Candoni A; Michelutti A; Simeone E; Damiani D; Baccarani M; Fanin R
Eur J Haematol; 2006 Oct; 77(4):293-9. PubMed ID: 16856922
[TBL] [Abstract][Full Text] [Related]
47. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
Gökbuget N; Basara N; Baurmann H; Beck J; Brüggemann M; Diedrich H; Güldenzoph B; Hartung G; Horst HA; Hüttmann A; Kobbe G; Naumann R; Ratei R; Reichle A; Serve H; Stelljes M; Viardot A; Wattad M; Hoelzer D
Blood; 2011 Sep; 118(13):3504-11. PubMed ID: 21715318
[TBL] [Abstract][Full Text] [Related]
48. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
49. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
[TBL] [Abstract][Full Text] [Related]
50. [A new purine analog in the treatment of hematologic malignancy. I. Fludarabine].
Vásová I; Penka M; Hájek R; Mayer J; Krahulcová E
Vnitr Lek; 1997 Jan; 43(1):45-50. PubMed ID: 9221567
[TBL] [Abstract][Full Text] [Related]
51. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
Shimony S; DeAngelo DJ; Luskin MR
Blood Adv; 2024 Jan; 8(1):23-36. PubMed ID: 37389830
[TBL] [Abstract][Full Text] [Related]
52. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
O'Connor OA; Heaney ML; Schwartz L; Richardson S; Willim R; MacGregor-Cortelli B; Curly T; Moskowitz C; Portlock C; Horwitz S; Zelenetz AD; Frankel S; Richon V; Marks P; Kelly WK
J Clin Oncol; 2006 Jan; 24(1):166-73. PubMed ID: 16330674
[TBL] [Abstract][Full Text] [Related]
53. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
54. Nelarabine associated myotoxicity and rhabdomyolysis.
Haider M; Rizvi SA; Kasi PM
Case Rep Hematol; 2015; 2015():825670. PubMed ID: 25866685
[TBL] [Abstract][Full Text] [Related]
55. Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: Case report and review of literature.
Ngo D; Patel S; Kim EJ; Brar R; Koontz MZ
J Oncol Pharm Pract; 2015 Aug; 21(4):296-300. PubMed ID: 24664478
[TBL] [Abstract][Full Text] [Related]
56. Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma.
Ravandi F; Gandhi V
Expert Opin Investig Drugs; 2006 Dec; 15(12):1601-13. PubMed ID: 17107284
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
Kathpalia M; Mishra P; Bajpai R; Bhurani D; Agarwal N
Ann Hematol; 2022 Aug; 101(8):1655-1666. PubMed ID: 35727338
[TBL] [Abstract][Full Text] [Related]
58. Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
Cooper TM
Ther Clin Risk Manag; 2007 Dec; 3(6):1135-41. PubMed ID: 18516261
[TBL] [Abstract][Full Text] [Related]
59. Clofarabine in adult acute leukemias: clinical success and pharmacokinetics.
Cooper T; Kantarjian H; Plunkett W; Gandhi V
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1417-23. PubMed ID: 15571270
[TBL] [Abstract][Full Text] [Related]
60. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
Rizzieri DA; Feldman E; Dipersio JF; Gabrail N; Stock W; Strair R; Rivera VM; Albitar M; Bedrosian CL; Giles FJ
Clin Cancer Res; 2008 May; 14(9):2756-62. PubMed ID: 18451242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
